The estimated Net Worth of Eric H. Siegel is at least $6.55 Millón dollars as of 1 September 2017. Eric Siegel owns over 1,820 units of Incyte stock worth over $1,486,901 and over the last 13 years Eric sold INCY stock worth over $5,065,281.
Eric has made over 26 trades of the Incyte stock since 2012, according to the Form 4 filled with the SEC. Most recently Eric exercised 1,820 units of INCY stock worth $117,481 on 1 September 2017.
The largest trade Eric's ever made was selling 57,481 units of Incyte stock on 14 May 2012 worth over $1,328,961. On average, Eric trades about 8,057 units every 50 days since 2011. As of 1 September 2017 Eric still owns at least 23,553 units of Incyte stock.
You can see the complete history of Eric Siegel stock trades at the bottom of the page.
Eric's mailing address filed with the SEC is EXPERIMENTAL STATION, ROUTE 141 AND HENRY CLAY RD, WILMINGTON, DE, 19880.
Over the last 21 years, insiders at Incyte have traded over $114,417,378 worth of Incyte stock and bought 24,211,970 units worth $713,884,116 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B... y Brothers Life Sciences Capi.... On average, Incyte executives and independent directors trade stock every 14 days with the average trade being worth of $4,355,654. The most recent stock trade was executed by Steven H Stein on 12 August 2024, trading 11,608 units of INCY stock currently worth $703,793.
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
Incyte executives and other stock owners filed with the SEC include: